12:00 AM
Mar 16, 2009
 |  BC Week In Review  |  Company News  |  Deals

Avexa, Cytopia, Progen deal

Progen proposed a A$40 million (US$25.5 million) share buyback at A$1.10 after the company's shareholders rejected a proposed merger with infectious disease company Avexa. The Avexa merger would have been a stock deal that was to be completed following a A$20 million share buyback. Progen said shareholders rejected the merger because they wanted a larger cash...

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >